Buloxibutid (C21) is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) recently completing a phase 2a study in IPF. Almee™ (an investigational medical ...

OncoNano Medicine announced that it will present a Trials in Progress poster at the upcoming 2024 ASCO Annual Meeting.

Semaglutide medications — including Ozempic and Wegovy — have been shown to reduce the risk of kidney failure and the risk of death among people with kidney disease and type 2 diabetes. In a trial led ...

Ozempic, Trulicity and Mounjaro were first approved to treat diabetes, however, in the last three years, the FDA has approved ...

A new so-called 'zombie drug' is appearing in street drugs across U.S. ( NewsNation) — Officials are sounding the alarm over ...

The centrally acting alpha2-adrenergic agonist allows for nighttime dosing and can be used with stimulants, the drug's ...

Live webcasts of the fireside chats will be available on the investor relations page of te Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcasts will be archived on ...

Popular weight loss drugs like Wegovy and Ozempic have changed the way many Americans are eating and as people taking these ...

Tokyo, Japan and Cambridge, UK, 30 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) today announced that it expects to receive $4.6 ...

A recent study in the Journal of Clinical Medicine found that oral semaglutide significantly improves glycemic control and ...

In the US, GLP-1 agonist drugs like Ozempic and Wegovy are already making people eat fewer calories and fats as they look to ...

Specific demographic, clinical, and financial characteristics are associated with glucagon-like peptide 1 (GLP-1) receptor ...